Radiopharm Theranostics Ltd (RADX) income statement
RADXNasdaqPharmaceutical PreparationsFiscal year ends June 30Also trades as RDPTF
Số liệu tài chính tới năm tài chính 2026, năm kết thúc ngày Jun 30, 2026Last filing: 20-F on Sep 30, 2026Score 6/30
$0.69+0.01 (+2.10%)
Close on Nov 18, 2026Market cap $8.09MP/E –Yield –
Radiopharm Theranostics Ltd income statement
Ratios
Latest available, balances at Jun 30, 2026
Profitability, FY2026
- Gross margin
- 9.5%
- Operating margin
- -2051.5%
- Net margin
- –
- Return on equity, FY2026
- –
Financial strength
- Current ratio
- 1.16
- Debt to equity
- –
- Debt to assets
- –
- Cash to current liabilities
- 21.9%
Valuation
- P/E ratio
- –
- Price to sales
- 2.92
- Price to book
- –
- Dividend yield
- –
See a number that looks wrong?